Back to Stocks

AKBA

Akebia Therapeutics, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Akebia Therapeutics is successfully navigating a critical transition from a legacy-product company to a high-growth rare kidney disease innovator.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Beneath the surface of Vafseo's growth lies a precarious financial structure characterized by a ticking clock on debt covenants.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every AKBA filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The 10-Q filing presents a classic biotech trade-off: a company with a proven, growing product in Vafseo and a sophisticated pipeline, balanced against a fragile balance sheet and heavy debt burdens. The immediate impact of the filing is the confirmation of Vafseo's commercial traction, which provides a necessary offset to the inevitable decline of Auryxia. However, the operational reality is a struggle for sustainability, as the company continues to report net losses and faces significant royalty outflows. Ultimately, the investment thesis hinges on whether the clinical success of the mid-stage pipeline can arrive before the financial pressures of the BlackRock loan and CSL Vifor obligations become untenable. The transition to a new headquarters in Waltham and the initiation of Phase 2 trials for AKB-097 signal a company attempting to scale, but the margin compression from inventory write-downs and high COGS suggests that operational efficiency remains a work in progress.

Selected Quarter

Core Takeaway

Akebia is successfully replacing Auryxia revenue with Vafseo growth, but is fighting a battle against its own debt structure and high operational costs.

Investor Lens

The trade-off is between the asymmetric upside of a multi-billion dollar pipeline and the immediate risk of a liquidity crisis driven by debt obligations.

Watch Next

Phase 2 basket trial initiation for AKB-097 in H2 2026 and quarterly cash burn trends.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.30Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

Cost of goods sold increased 61% due to inventory write-downs and manufacturing costs.

margin compression
70%
bearishMay 7

Shift from $6.1M net income to $9.1M net loss year-over-year.

earnings miss
60%
bearishMay 7

BlackRock covenant non-compliance creates significant risk of forced dilutive financing.

dilution risk
70%
bullishMay 7

Acquisition of AKB-097 expands pipeline into multi-billion dollar rare kidney disease markets.

acquisition
80%
bearishMay 7

Cost of goods sold increased 61% due to inventory write-downs and manufacturing costs.

margin compression
70%
bearishMay 7

Shift from $6.1M net income to $9.1M net loss year-over-year.

earnings miss
60%
bearishMay 7

BlackRock covenant non-compliance creates significant risk of forced dilutive financing.

dilution risk
70%
bullishMay 7

Acquisition of AKB-097 expands pipeline into multi-billion dollar rare kidney disease markets.

acquisition
80%
bearishMay 7

Cost of goods sold increased 61% due to inventory write-downs and manufacturing costs.

margin compression
70%
bearishMay 7

Shift from $6.1M net income to $9.1M net loss year-over-year.

earnings miss
60%
bearishMay 7

BlackRock covenant non-compliance creates significant risk of forced dilutive financing.

dilution risk
70%
bullishMay 7

Acquisition of AKB-097 expands pipeline into multi-billion dollar rare kidney disease markets.

acquisition
80%
bearishMay 7

Cost of goods sold increased 61% due to inventory write-downs and manufacturing costs.

margin compression
70%
bearishMay 7

Shift from $6.1M net income to $9.1M net loss year-over-year.

earnings miss
60%
bearishMay 7

BlackRock covenant non-compliance creates significant risk of forced dilutive financing.

dilution risk
70%
bullishMay 7

Acquisition of AKB-097 expands pipeline into multi-billion dollar rare kidney disease markets.

acquisition
80%
bearishMay 7

Cost of goods sold increased 61% due to inventory write-downs and manufacturing costs.

margin compression
70%
bearishMay 7

Shift from $6.1M net income to $9.1M net loss year-over-year.

earnings miss
60%
bearishMay 7

BlackRock covenant non-compliance creates significant risk of forced dilutive financing.

dilution risk
70%
bullishMay 7

Acquisition of AKB-097 expands pipeline into multi-billion dollar rare kidney disease markets.

acquisition
80%
bearishMay 7

Cost of goods sold increased 61% due to inventory write-downs and manufacturing costs.

margin compression
70%
bearishMay 7

Shift from $6.1M net income to $9.1M net loss year-over-year.

earnings miss
60%
bearishMay 7

BlackRock covenant non-compliance creates significant risk of forced dilutive financing.

dilution risk
70%
bullishMay 7

Acquisition of AKB-097 expands pipeline into multi-billion dollar rare kidney disease markets.

acquisition
80%
bearishMay 7

Cost of goods sold increased 61% due to inventory write-downs and manufacturing costs.

margin compression
70%
bearishMay 7

Shift from $6.1M net income to $9.1M net loss year-over-year.

earnings miss
60%
bearishMay 7

BlackRock covenant non-compliance creates significant risk of forced dilutive financing.

dilution risk
70%
bullishMay 7

Acquisition of AKB-097 expands pipeline into multi-billion dollar rare kidney disease markets.

acquisition
80%

Filing History

10-QMay 7, 2026
Expand Sequence

The 10-Q filing presents a classic biotech trade-off: a company with a proven, growing product in Vafseo and a sophisticated pipeline, balanced against a fragile balance sheet and heavy debt burdens. The immediate impact of the filing is the confirmation of Vafseo's commercial traction, which provides a necessary offset to the inevitable decline of Auryxia. However, the operational reality is a struggle for sustainability, as the company continues to report net losses and faces significant royalty outflows. Ultimately, the investment thesis hinges on whether the clinical success of the mid-stage pipeline can arrive before the financial pressures of the BlackRock loan and CSL Vifor obligations become untenable. The transition to a new headquarters in Waltham and the initiation of Phase 2 trials for AKB-097 signal a company attempting to scale, but the margin compression from inventory write-downs and high COGS suggests that operational efficiency remains a work in progress.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.